NCT03519854View on ClinicalTrials.gov

Efficacy, Safety and Pharmacokinetics of Sugammadex (Org 25969; MK-8616) at 3 Different Time Points After 0.6 mg/kg Esmeron® in Male Participants (P05940; MK-8616-020).

PHASE2CompletedINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

December 1, 2002

Primary Completion Date

June 1, 2003

Study Completion Date

June 1, 2003

Conditions
Neuromuscular Blockade
Interventions
DRUG

Placebo

0.9% NaCl administered as a fast IV bolus dose (within 30 seconds).

DRUG

Sugammadex

Sugammadex administered as a fast IV bolus dose (within 30 seconds), dosed according to participant actual body weight.

DRUG

Esmeron®

Esmeron® administered at 0.6 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT03519854 - Efficacy, Safety and Pharmacokinetics of Sugammadex (Org 25969; MK-8616) at 3 Different Time Points After 0.6 mg/kg Esmeron® in Male Participants (P05940; MK-8616-020). | Biotech Hunter | Biotech Hunter